ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0396

Esophageal Involvement and Gastroesophageal Reflux Disease in Patients with SSc-ILD: Data from a Sub-Study of the SENSCIS Trial
Abstract Number: 1170

Establishment and Validation of a Didactic Musculoskeletal Ultrasound Course for Dermatologists Using an Innovative Handheld Ultrasound System
Abstract Number: 1048

Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
Abstract Number: 1764

Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients
Abstract Number: 0622

Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California
Abstract Number: 0610

Evaluating Patient No Show Rates to Rheumatology Appointments Across a Regional Healthcare System
Abstract Number: 1066

Evaluation of a Non-Face to Face Multidisciplinary Health Care Model in a Population with Rheumatoid ArthritisVulnerable to Covid-19 in a Health Emergency Situation
Abstract Number: 1701

Evaluation of Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis Patients, Treated with Biological Agents: 6-month Follow-up
Abstract Number: 1160

Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Abstract Number: 0088

Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data
Abstract Number: 1420

Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 1211

Evaluation of the Cervical Involvement Frequency and Associated Risk Factors in Patients with Rheumatoid Arthritis
Abstract Number: 1029

Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry
Abstract Number: 0770

Evaluation of the Lupus Low Disease Activity State (LLDAS) vs. the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K Score in a Pediatric Systemic Lupus Erythematosus Cohort
Abstract Number: 0859

Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].